Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Conference News EAS 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Michael O'Riordan

May 23, 2023

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

Presentation Controversies and Advances 2019

AngiopoetinLike-3 ( ANGPTL-3) : A Novel Target for Dyslipidemia

Presenter: P.K.Shah

November 15, 2019

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

Advertisement

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

What’s Going to Be Hot at AHA 2025?

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

FDA Approves Evinacumab for Rare Homozygous FH

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

AngiopoetinLike-3 ( ANGPTL-3) : A Novel Target for Dyslipidemia

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content